Status:
ACTIVE_NOT_RECRUITING
Daily Topical Rapamycin for Vitiligo
Lead Sponsor:
Medical University of South Carolina
Collaborating Sponsors:
American Skin Association
Conditions:
Vitiligo
Eligibility:
All Genders
13+ years
Phase:
PHASE2
Brief Summary
In current Dermatology practice, options for vitiligo remain limited. The purpose of this study is to determine if once daily dosed topical rapamycin is effective for the treatment of patients with vi...
Eligibility Criteria
Inclusion
- Patients 13 years of age and older
- Patients with nonsegmental vitiligo
Exclusion
- Patients with segmental or mucosal vitiligo
- Patients with contraindication to use of rapamycin
- Patients with history of transplant
- Patients with a history of natural immunodeficiency
- Patients with a history of artificially induced immunodeficiency
- Patients with a history of a serious or life-threatening infection
- Patients taking CYP3A4 inhibiting medications
- Patients taking strong CYP3A4 inducers
- Patients undergoing current treatment for vitiligo
- Women that are or may become pregnant
Key Trial Info
Start Date :
July 28 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 1 2026
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT05342519
Start Date
July 28 2022
End Date
August 1 2026
Last Update
August 14 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Medical University of South Carolina
Charleston, South Carolina, United States, 29425